Share Consolidation and Total Voting Rights

Share Consolidation and Total Voting Rights

Chippenham, UK - 14 October 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Company") announces that the Share Consolidation by which every 13 Existing Ordinary Shares of £0.00025 each will be consolidated into 12 New Ordinary Shares of £0.000271 each will take effect from 8.00 a.m. (London time) today (or as soon as practicable thereafter) ("Admission"). At that time, 615,305,592 New Ordinary Shares of £0.000271 each (under ISIN: GB00BKM2MW97) will be admitted to the premium listing segment of the Official List and to trading on the London Stock Exchange's main market for listed securities.

Each shareholder's percentage holding in the total issued share capital of the Company immediately before and after the implementation of the Share Consolidation will (save in respect of fractional entitlements) remain unchanged. The New Ordinary Shares will have the same rights, including voting and dividend rights, as the Existing Ordinary Shares.

With effect from Admission, share certificates in respect of the Existing Ordinary Shares will cease to be valid and it is expected that share certificates in respect of the New Ordinary Shares will be dispatched on 25 October 2019 to shareholders who hold their shares in certificated form. Shareholders who held their Existing Ordinary Shares in CREST will have the New Ordinary Shares to which they are entitled automatically credited to their CREST accounts at approximately 8.00 a.m. (London time) today (or as soon as practicable thereafter).

Vectura confirms that the shares currently held by its directors and their connected persons will also be consolidated with effect from Admission, but that their relevant percentage interests following consolidation will remain the same as those prior to consolidation (subject to any fractional entitlements resulting from the Share Consolidation). Their expected interests in the New Ordinary Shares in the Company following consolidation will be as follows:

Total Voting Rights

As at close of business on 11 October 2019, the Company's issued share capital consisted of 666,581,058 Existing Ordinary Shares of £0.00025, each of which had one voting right. The Company does not hold any shares in treasury. Following the Share Consolidation, the Company's issued share capital will consist of 615,305,592 New Ordinary Shares of £0.000271 each, each of which will have one voting right. This figure of 615,305,592 may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, New Ordinary Shares under the FCA's Disclosure Guidance and Transparency Rules.

- Ends-

Definitions

"Admission" means the admission of the New Ordinary Shares (i) to the premium segment of the Official list of the United Kingdom Listing Authority and (ii) to trading on the Main Market becoming effective, in accordance with, respectively, the Listing Rules and the Admission and Disclosure Standards;

"CREST" means the relevant system (as defined in the Uncertificated Securities Regulations 2001 (as amended)) in respect of which CRESTCo UK & Ireland Limited is the operator (as defined in the Uncertificated Securities Regulations 2001 (as amended));

"Existing Ordinary Shares" means the ordinary shares of £0.00025 each in the capital of the Company prior to the Share Consolidation;

"FCA" means the United Kingdom's Financial Conduct Authority (or any successor body in respect thereof);

"Listing Rules" means the Listing Rules of the FCA made for the purposes of Part VI of the Financial Services and Markets Act 2000, as amended;

"Main Market" means the London Stock Exchange plc's main market for listed securities;

"New Ordinary Shares" means the ordinary shares of £0.000271 each in the capital of the Company resulting from the Share Consolidation; and

"Share Consolidation" means the consolidation of every 13 Existing Ordinary Shares into 12 New Ordinary Shares.

For more information, please contact:

Consilium Strategic Communications +44 (0)20 3709 5700

Mary-Jane Elliott / Sue Stuart / David Daley

About Vectura

Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. 

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com